Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1
August 04, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
The natural history study will generate data to further the ongoing efforts of the myotonic dystrophy research community to understand disease progression and identify potential clinical outcome...
Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer
July 19, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics to Present at William Blair Biotech Focus Conference
July 06, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
June 01, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Reports First Quarter 2022 Financial Results
May 12, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
Second clinical candidate, ENTR-701, announced for the potential treatment of myotonic dystrophy type 1 On track to submit Investigational New Drug application to the U.S. Food and Drug...
Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022
May 11, 2022 09:30 ET
|
Entrada Therapeutics, Inc.
New non-human primate data demonstrate a durability of response through 12 weeks for lead clinical candidate, ENTR-601-44, for the potential treatment of Duchenne muscular dystrophy Second...
Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference
May 10, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 15, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022 $291.1 million in cash and cash equivalents as of December 31, 2021 to advance pipeline of...
Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference
February 23, 2022 08:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel
January 05, 2022 08:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...